from different species of the same genus or different Allergen extracts are prepared from a wide variety of source allergen sources all together. Thus, the use of this materials including pollens, fungi, arthropods, animal danders, type of coding system to assign allergen specificity foods, and dusts. The composition of allergen extracts can vary should be avoided to minimize confusion when depending on the allergen source, manufacturing process, and comparing products from different manufacturers. storage conditions. Allergen-specific immunoglobulin E (IgE) Allergen specificities should include the complete alassays and skin tests employ a variety of allergen-containing lergen name (genus and species), and each manufacreagents that confer specificity on the test. Given that the aller-turer should make this available when requested. gen source materials are heterogenous mixtures of proteins, The WHO/IUIS Allergen Nomenclature Subcommitglycoproteins, carbohydrates, and other substances that are tee, an international effort of scientists to promote not allergenic, it is not unexpected that variability exists be-uniformity in allergen nomenclature, provides infortween test results obtained with different allergen-containing mation regarding primary allergen sources and reagents. Variability within a single manufacturer's allergen characterized purified allergens and maintains a deproduct can be controlled by using reproducible extraction and tailed list of currently characterized purified allerprocessing procedures, single large lots of allergen source ma-gens that are recognized by the organization. Allerterials, and solid-phase supports. These controls do not, how-gens are designated according to the accepted ever, ensure the consistency of products between manufactur-taxonomic name of their source, using the first three ers or laboratories because allergen source materials, letters of the genus, space, the first letter of the spemanufacturing procedures, and acceptance criteria for allergen cies, space, and an Arabic number. The numbers are reagents may vary. ᭧ 1997 Academic Press assigned on the basis of their order of identification, and the same number is generally used to designate homologous allergens of related species: Der p 1 refers to the first dust mite allergen identified from Dermatophagoides pteronyssinus and Der f 1 refers to the homologous allergen from Dermatophagoides Hundreds of allergen-containing reagents are rou-farinae. The recently revised nomenclature for allertinely employed for skin testing and immunoglobu-gens includes a proposed system for allergen genes, lin E (IgE) antibody assays. Allergen products are mRNAs, cDNAs, and recombinant and synthetic classified by the manufacturer into different aller-peptides of allergenic interest (1
designated 1 g of pollen as containing 1 million Noon v and the PNU systems become apparent when one considers the fact that (i) changing extraction condiunits: A 1/10 (w/v) extract prepared by extracting 1 g of pollen in 10 mL of extraction fluid would contain tions can lead to significant variability in the composition and potency of allergen extracts, (ii) most pro-100,000 Noon units/mL. This weight-by-volume (w/ v) system has been extended to virtually all allergen teins in extracts are not allergens, and (iii) extracts can deteriorate without any change in their protein source materials and is still one of the most widely used in clinical practice. When it became obvious content.
The discovery of IgE antibodies and the developthat most allergens were proteins, the protein nitrogen unit (PNU) was proposed as a method of stand-ment of immunoassays that measure allergen-specific IgE led to the use of (radioallosorbent test) RAST and ardizing allergen extracts (3) . One milligram of protein nitrogen is equivalent to 100,000 PNU. The (enzyme-linked immunosorbent assay (ELISA) inhibition procedures in allergen standardization (4) . In this assay has been standardized by the U.S. Food and Drug Administration and is routinely used by all assay, dilutions of fluid-phase reference and test allergen extracts are allowed to compete with the solid-U.S. manufacturers. The limitations of both the w/ phase reference allergosorbent for binding to IgE anti-of suitable numbers of patients (especially for esoteric allergens) can limit the validity of some results. bodies from a pool of allergic serum. The assay results Skin testing gives a direct biological estimate of pohave been correlated with the overall biological potency in allergic subjects; in vitro assays (e.g., ELISA tency of extracts, but the approach is limited by the inhibition) have wide applicability and are good preability of the IgE to bind the allergen and the variabildictors of overall allergenic potency, and major allerity of the specificity and concentration of the IgE in gen assays are precise, accurate, and easy to perform serum from the selected patients.
on a routine basis. The Noon (w/v) unit, PNU, and The identification and purification of major allera variety of analytical techniques such as isoelectric genic components from a number of important allergen focusing, SDS-PAGE, crossed-immunoelectrophoresources have allowed for the direct measurement of sis, and immunoblotting have proven their utility in specific allergen content in allergen extracts. Methods the qualitative analysis of allergen extracts. While based on polyclonal and monoclonal antibodies recogeach of these methods have made and will continue to nizing major allergens have been successfully emmake essential contributions toward the standardizaployed for extract standardization (5) (6) (7) . This aption and quality control effort, problems still exist that proach is not dependent upon the variation in the are inherent to allergenic extracts. specificity of patient's IgE antibodies, but requires the Only a limited number of standardized allergen measurement of most if not all relevant allergens (maextract preparations have been approved by the U.S. jor and minor) in an extract. If important allergens FDA for commercial distribution (Table 1 ). The prothat are responsible for clinical symptoms in some pacess of standardizing allergen extracts is a timetients are not measured, diagnostic and therapeutic consuming process of characterizing prospective refefficacy may not be predictable.
erence allergen extract preparations, identifying Two methods based upon quantitative skin testing major and minor allergenic components, measuring are currently used for allergen extract standardiza-biologic potency in clinically characterized sensitized tion. In the U.S. method (8) , extracts are evaluated for human subjects, developing in vitro assays that pretheir ability to induce a mean erythema diameter sum dict biological potency, obtaining licenses for comof 50 mm after intradermal injection (ID 50 EAL, or in-mercial distribution, and putting in place a lot retradermal dilution for 50-mm sum of erythema deter-lease system to monitor the regulatory compliance mines the allergy unit), and in the Nordic method (9), extract potency is related to the wheal size induced by histamine in prick testing. The HEP (histamine precision; the patient selection criteria and availability by each allergen product manufacturer. On average, qualitative methods can be employed to monitor the consistency and reproducibility of allergen source mathis process has taken approximately 10 years from the initial discovery of a major allergen to commer-terials and extracts. Isoelectric focusing and SDS-PAGE banding patterns are compared to reference excialization of a standardized extract.
tracts to establish the identity and protein composition of allergen extracts. This method is especially important with grass pollen extracts, since microscopic
ALLERGEN SOURCE MATERIALS
examination of pollen grains cannot be used to differentiate the different grass species. Furthermore, the Table 2 shows the variation in the major allergen major pollen allergens of most grass species are highly (Amb a 1) content of short ragweed pollen collected cross-reactive, and species-specific antibody reagents between 1980 and 1995 from the same location and for each grass species are not available. extracted identically. Extracts prepared from pollen Pure fungal cultures can be sustained in the labocollected in 1981 contained almost 10 times more Amb ratory, but their composition may vary depending a 1 than those prepared from pollen collected in 1987. on the culture conditions, the strain used, and By measuring the major allergen content of short rag-whether the fungal mat and the spent medium are weed pollen lots prior to extraction and selectively harvested. Some strains of Alternaria alternata will combining them, one can reproducibly manufacture produce significant quantities of the major allergen short ragweed extracts (1/10 w/v) with a consistent Alt a 1 only under certain conditions, and some Amb a 1 content. This practice increases the reproduc-strains will not produce detectable quantities under ibility of extract potency in spite of the variability of any condition. A standardization approach based on the major allergen content of the source material and the selection of A. alternata strains to develop a sincan be applied to other pollen source materials for gle Alternaria preparation that contains the full rewhich the major allergens can be measured.
portoire of relevant allergens has been proposed (10). Since no single strain appears to be suitable for this, When specific allergen content cannot be measured, b Cat albumin content determined by radial immunodiffusion and reported in terms of mg/mL based a purified cat albumin reference.
multiple strains will most likely have to be incorpo-cat extracts are prepared from the hair, dander, skin scrapings, or pelts or from combinations of these rated.
Dermatophagoides mites are grown as pure cul-sources. Extract from these sources can yield equivalent biological potencies when calibrated according tures; however, qualitative differences can be detected among extracts prepared from source materi-to their major allergen (Fel d 1) content, but will differ in the concentration of another important alals from different producers. Some batches of source materials may contain more fecal material than oth-lergen, cat albumin. Thus, the albumin concentrations of standardized (10,000 BAU/mL) cat extracts ers and thus lead to extracts with a higher specific Group 1 allergen content. Removal of the growth containing approximately 15 Fel d 1 units/mL may vary 10-to 500-fold (Table 4) . To reflect this signifimedium may not be complete during harvesting, leading to extracts containing varying amounts of cant variation in albumin concentration, cat extracts are labeled as either cat hair or pelt. extraneous proteins. Table 3 shows the Der f 1 and Der f 2 content of four different manufacturers' standardized (10,000 AU/mL) D. farinae extracts. The results suggest that although biological standardization may ensure batch-to-batch consistency of lots STABILITY OF ALLERGEN EXTRACTS produced by one manufacturer using mite source materials prepared in a reproducible manner, consistency between lots from different manufacturers Extract manufacturing procedures may vary, and extraction conditions, such as the buffer used, ex-(using qualitatively different source materials) may not be ensured. In practice, this means that switch-traction temperature, and extraction time, and the incorporation of stabilizers can influence final proding from one manufacturer's standardized mite extract to another's must take into account the possible uct quality. Storage conditions, especially temperature and extract dilution, can also affect product differences in specific allergen composition that could exist. quality and potency (11) . Endogenous proteases can lead to the degradation of some allergens during The allergen composition of extracts derived from animal sources can also vary greatly. For example, storage (12) . The most effective methods for stabiliz-
FIG. 1. (A)
Coating titrations of crude (l), dialyzed (᭡), and G25 void () extract fractions prepared from a single lot of cat dander source material. Fivefold serial dilutions starting with a 100 mg protein/mL preparation were made in carbonate coating buffer, pH 9.6, and used to coat Corning EIA microtiter plate wells. The source of IgE antibodies was a serum pool obtained from 18 history and skin test-positive subjects (ZE-P3), and the serum pool was applied to the allergosorbent at a dilution of 1:10. The IgE bound was detected using an alkaline phosphatase-labeled anti-human IgE second antibody (Sanofi Diagnostics Pasteur, Chaska MN) and p-nitrophenyl phosphate substrate. The absorbance at 405 nm was measured after incubation with substrate for 30 min. (B) IgE antibody titrations of the control anti-cat serum pool ZE-P3 using crude (l), dialyzed (᭡), and G25 void () allergosorbents. Twofold serial dilutions of the serum pool were incubated with Corning EIA microtiter plate wells coated with the cat dander extract at 10 mg protein/mL, and the bound IgE antibodies were detected as described for A.
ing
Because allergen extracts contain both heat-stable and unstable allergens and the patient's reactivity toward each allergen varies, stability studies with partially degraded extracts may yield unpredictable VARIABILITY OF ALLERGEN SOURCE and equivocal results. For this reason, a conserva-MATERIALS AND ALLERGEN-SPECIFIC tive approach to the design of stability studies would IgE ASSAYS be to assign the shelf-life of allergen-containing reagents based on the activity of the most labile allergenic component in the extract. While this approach
Whether the immunoassay is designed to detect and measure specific IgE antibodies in serum sammay ensure that all allergens within a given extract remain reactive, one could argue that a single aller-ples or to measure the potency of allergenic extracts, the allergen-containing reagent is critical for obgen molecule should not represent the diagnostic utility of a mixture that contains other major and taining results that are reproducible and comparable between laboratories. A common practice used minor allergens that may be useful in detecting IgE a Results for individual allergic sera reported as relative units with respect to the positive control pool (POS) using the formula, units Å (T/R) 1 100, where T is the absorbance units obtained with the individual test serum sample, and R is the absorbance units obtained with the positive control serum pool from the same assay. A negative control serum pool (NC) obtained from history and skin testnegative subjects were included as a measure of nonspecific binding. Results for the allergen-specific control sera are reported as arbritary units based on the absorbance units (11000) measured after 30 min of incubation with p-nitrophenyl phosphate substrate. The Fel d 1 and cat albumin concentrations of the allergen extracts used to prepare the allergosorbents were determined by radial immunodiffusion (11) using the CBER/FDA reference Fel d 1 (1 unit Å 4 mg) and Sigma cat albumin for standards and precipitating sheep anti-Fel d 1 (CBER/FDA) and rabbit anti-cat albumin (Greer) antisera: Cat pelt, 0.20 mg/mL in research as well as in commercial laboratories is assumed to be defined by the composition of the extract and its source without confirming the successto prepare allergen allergosorbents by either passive adsorption or covalent binding of allergens to a solid-ful coupling of the relevant antigens to the solid phase. Quality control procedures using individual phase support. The allergen sources used include extracts prepared from a wide variety of raw materi-control serum samples and animal antisera with defined specificities can be performed to operationally als known to contain IgE-binding proteins or antigens. In most applications, it is desirable that all demonstrate the specificity of an allergosorbent. Examples are presented for the preparation of a cat relevant allergenic epitopes be available on the solid phase. The specificity of the allergosorbents is often allergen extract allergosorbent.
FIG. 2. ELISA inhibition assay employing cat dander (A), cat pelt (B)
, cat saliva (C), and cat pelt/dander (D) allergosorbents. Dialyzed extracts prepared from cat dander (l), pelt (᭡), saliva (), and cat pelt/dander (᭺) were co-incubated in the microtiter plate wells at various concentrations with the control serum pool ZE-P3 (at a final dilution of 1:10) for 6-8 h before the addition of the alkaline phosphatase-labeled anti-human IgE second antibody. The absorbance at 405 nm was measured 30 min after addition of the p-nitrophenyl phosphate substrate, and the percentage inhibition of IgE binding was calculated using the formula, % inhibition Å [(A 0 0 A 1 )/A 0 ] 1 100, where A 0 is the absorbance measured in the absence of inhibitor, and A 1 is the absorbance measured in the presence of inhibitor. A grass pollen extract was used as a nonspecific inhibitor control and was found to inhibit IgE binding õ20% at up to 1 mg/mL protein concentrations (data not shown).
Several source materials can be used to produce bind specific IgE antibodies from 18 history and skintest-positive sera (Table 5 ). In addition, each solidhighly reproducible and specific reagents for the measurement of cat allergen-specific IgE antibodies. Cat phase allergen was examined for the presence of the known cat allergens Fel d 1 and cat albumin using dander, saliva, and pelt are known to contain detectable levels of allergens that bind IgE antibodies from monospecific rabbit polyclonal antibodies. The results were highly variable, and no single allergosorbent cat-sensitive individuals and are thus frequently used as raw materials for the production of allergosorbents yielded a positive reaction in all 18 serum samples.
The cat pelt allergosorbent identified one serum samin specific IgE antibody immunoassays (13-16). More recently, attempts have been made to utilize purified ple (No. 6) as positive that was not identified by either the cat dander or the cat saliva allergosorbents, but it native and recombinant Fel d 1, the major allergen of cat origin, to measure IgE antibody (17) (18) (19) (20) .
failed to detect IgE antibodies in five samples (Nos. 4, 5, 8, 14 , and 16). The cat saliva allergosorbent failed Extracts prepared from these sources were evaluated using the same solid-phase support and a serum pool to detect IgE antibodies in 6 of 18 samples. The cat dander allergosorbent successfully identified 17 of the composed of 18 history and skin test-positive human subjects. Since the plastic solid-phase supports com-18 samples as positive. Based on the results obtained with the monospecific rabbit antisera, the deficiencies monly used in enzyme immunoassay applications have limitations in binding capacities, various methods have noted with the allergosorbents could be attributed in part to their relative lack of sensitivity toward debeen investigated to enhance the binding of the specific allergen content of extracts and reduce adsorption of tecting specific anti-Fel d 1 or anti-cat albumin antibodies. For example, the cat pelt allergosorbent showed nonallergenic components to the solid phase. Removal of low-molecular-weight contaminants from the extract reduced binding of anti-Fel d 1 antibodies, while the cat dander allergosorbent showed reduced binding of by either dialysis or Sephadex G-25 gel filtration greatly improves the binding of IgE antibodies to the anti-cat albumin antibodies. The Fel d 1 and albumin content and their ratios in the respective extracts are allergosorbent as indicated in Fig. 1 . All extracts give binding curves that indicate that saturation of the solid-different; Fel d 1 is the major component in cat dander and saliva extracts, and albumin is the major compophase support is achieved at a protein concentration of about 10 mg/mL. Figure 1A shows a representative nent in cat pelt extracts. The difficulty in achieving conditions of allergen excess on the allergosorbents, experiment conducted with cat dander extracts. Serum titration curves (Fig. 1B) suggest that although condi-especially with the minor components, may explain the differences observed in the antibody-binding efficientions of allergen excess could not be achieved with the plastic support, the dynamic range of allergen-specific cies. Different solid phases may also favor the adsorption of different allergenic components, and some allerIgE assays was increased by such procedures.
Each allergosorbent was evaluated for its ability to gens may not bind at all. Nonetheless, the cat pelt a Relative potency values were determined by parallel line regression analysis (CBER/FDA Manual of Methods) using a serum pool obtained from 18 history and skin test-positive subjects (ZE-P3). Each extract served as the reference extract in its respective allergosorbent system and by definition was given a relative potency value of 1.00. The 2SD upper and lower limits for N Å 3 are presented in parentheses.
b Saliva extract relative potency assays failed the t test for parallelism at p Å 0.01 when performed in the heterologous allergosorbent systems and therefore were not valid (see Fig. 2 ).
and cat hair/dander sources appeared to contain all ALLERGEN EXTRACT POTENCY the allergen specificities that were detectable by IgE DETERMINATIONS BY ELISA INHIBITION antibodies in the human sera. Based on these findings,
ARE DEFINED BY BOTH REFERENCE
an allergosorbent that uses an extract mixture with ALLERGEN AND ANTISERUM equal amounts of Fel d 1 and albumin concentrations CHARACTERISTICS was evaluated. After optimizing for coating using the control serum pool, the sensitivity of the mixed extract allergosorbent was evaluated with the same 18 human
Immunoassays based on the competition of fluidsera. In this experiment, all 18 sera were identified as phase and solid-phase allergens for specific antibodies positive for specific IgE antibodies, and both the Fel are commonly employed for potency estimations of ald 1 and the cat albumin specificities appeared to be lergenic extracts. The standardization of commercial extracts used in the United States for diagnosis and adequately represented on the solid phase (Table 5 ). immunotherapy of allergic disease is based on ELISA bent should (i) represent the allergen specificities present in both the reference and the test extracts, inhibition assays (22), and modifications of the assay format have been used to detect and measure specific (ii) produce parallel reference and test inhibition regression lines, and (iii) allow for inhibitions apallergen levels in environmental samples (24).
The performance of the cat allergen allergosor-proaching 100% for both reference and test extracts. From the perspective of allergenic extract standardbents was evaluated in ELISA inhibitions designed to determine the relative potencies of cat allergen ization, it might be argued that the use of a single reference allergen extract as the standard for conextracts ( Fig. 2 and Table 6 ). Each of the allergen extracts was a potent inhibitor when examined with trolling all cat-derived allergen products requires that each manufacturer utilize nearly identical its homologous allergosorbent. Qualitative differences between extracts could be identified by the source materials and production procedures. Because different manufacturers or laboratories use lack of parallelism in the dose-response curves generated with the cat saliva extract when tested in the different allergen source materials and processing procedures, it appears more appropriate to establish cat pelt and cat dander allergosorbents. The t test for parallelism between the regression lines gener-individual in-house reference extract preparations that reflect the compositional and biochemical charated by the extract dose-response curves identified gross qualitative differences and was used to estab-acteristics of each manufacturer's product.
The choice of an appropriate allergic serum pool lish assay validity. Depending on the allergosorbent used, different relative potencies were calculated for can also lead to disparate potency determinations by ELISA inhibition. The reference serum selection the allergen extracts. For example, when the cat dander allergosorbent system was used, the relative criteria employed may favor the detection of some allergenic components over others and bias the popotency of the cat pelt extract was approximately 10% that of the cat dander extract. In contrast, when tency estimates toward those components as defined by the serum IgE antibody specificities. In the experthe homologous cat pelt allergosorbent system was used, the cat pelt extract was about three times as iment shown in Fig. 3 , an ELISA inhibition assay was conducted using the optimized cat pelt/dander potent as the cat dander extract. Finally, when compared in the mixed cat dander/pelt or cat saliva sys-allergosorbent and a reference serum pool selected on the basis of reactivity toward cat dander or pelttems, no significant difference in the potencies of the cat pelt and cat dander extracts could be detected.
derived allergens. The calculated relative potencies of the respective extracts differed by nearly a factor These results show that ELISA inhibition assays are sensitive to both qualitative and quantitative of 3, depending upon the serum pool used (Table 7) .
Furthermore, the discrepencies were magnified at differences between extracts derived from cat source materials and underscore the importance of the na-higher serum dilutions (i.e., 1/80 vs 1/10 dilutions), indicating that minor IgE antibody specificities may ture of the allergen allergosorbent when determining allergen extract potency. Ideally, the allergosor-have been diluted to extinction. The possibility (20)) using control sera 6 (anti-cat pelt serum) and 5 (anti-cat dander serum) described in Table 3 . The cat pelt/dander extract served as the reference extract and by definition was given a relative potency value of 1.00. The 2SD upper and lower limits for N Å 3 are presented in parentheses.
therefore exists that by diluting the reference sera sure their identity, purity, and consistent processing.
The design and validation of immunoassays for the one may affect not only the sensitivity of the assay, detection of allergen-specific IgE antibodies or for the but also its specificity (Fig. 4) . measurement of allergen extract potency require the use of well-characterized reference reagents for the CONCLUSIONS preparation of allergosorbents and control antibodies. Uniformity in the use of established allergen nomenThe inherent variability of natural allergen source materials requires quality control procedures that en-clature and allergen extract standardization provide   FIG. 4 . Effect of pooling of individual sera (A) and dilution (B) on the specificity of control sera used for allergen standardization. The bar graphs illustrate the relative concentrations of IgE antibodies from four individuals (a-d) for three allergen specificities (1-3). When these sera are pooled, the concentration of IgE antibodies directed toward minor allergens becomes underrepresented and the major IgE antibody specificity predominates. Dilution of the pooled sera further dilutes the minor IgE antibody specificities, often beyond the detection limit of IgE antibody assays.
approaches toward comparability and consistency be-REFERENCES tween products from different manufacturers.
The specificity of a particular immunoassay
